Contact
Please use this form to send email to PR contact of this press release:
Navrogen Awarded Patent for NAV-001 Anti-Mesothelin Antibody-Drug Conjugate (ADC) Targeting Difficult-to-Treat Cancers
TO:
Nicholas Nicolaides
Navrogen Inc
+1 610-399-2717